Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Real-time Euronext Paris Other stock markets 09:29:56 2024-06-27 EDT			5-day change	1st Jan Change
5.89 ^EUR	-2.64%		-6.66%	+37.62%

06-24	OSE: market welcomes CAR-T agreement	CF
06-24	OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OSE: market welcomes CAR-T agreement	06-24	CF
OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center	06-24	CI
OSE: treatment prospects with therapeutic mRNA	06-20	CF
OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco	06-20	CI
OSE Immuno: positive analysis presented at ATC congress	06-05	CF
OSE Immuno: towards an evolution of the Board of Directors	05-30	CF
OSE, Boehringer Ingelheim Expand Partnership for Immuno-oncology Programs	05-22	MT
OSE: agreement extended with Boehringer Ingelheim, share price rises	05-22	CF
OSE Immunotherapeutics SA and Boehringer Ingelheim Expand Collaboration to Develop First-In-Class Treatments for Cancer and Cardio-Renal-Metabolic Diseases	05-22	CI
OSE: licensing agreement with AbbVie enters into force	04-17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	04-17	MT
OSE Immunotherapeutics SA's Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	04-16	CI
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	04-11
Ose Immuno receives funding from Bpifrance	04-11	CF
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation	03-18	CF
OSE Immuno: recruitment completed for UC trial	03-18	CF
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	03-18	CI
OSE Immuno: share price soars following partnership with AbbVie	02-28	CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody	02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Highlights

Filters